BCL-XL-IN-5

Overview

BCL-XL-IN-5 is an orally active, highly selective BH3-mimetic BCL-XL inhibitor with a cK i of 7.96 pM. BCL-XL-IN-5 triggers caspase-3 activation and robust PARP cleavage to initiate apoptosis in BCL-XL-dependent MOLT-4 T-cell acute lymphoblastic leukemia cells. BCL-XL-IN-5 serves as a potent selective probe for investigating BCL-XL-dependent malignancies, such as acute lymphoblastic leukemia.

Application

Products | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Acute Lymphoblastic Leukemia | Products > Disease Areas > Cancer | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Bcl-2 Family | Products > Signaling Pathways > Caspase | Products > Signaling Pathways > PARP | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-184471
• CAS No.: 2599098-78-7
• Molecular Formula: C36H38N8O2S
• Molecular Weight: 646.80
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source